Research Analysts Set Expectations for BLFS Q4 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities research analysts at Northland Capmk issued their Q4 2025 EPS estimates for BioLife Solutions in a report released on Wednesday, January 8th. Northland Capmk analyst C. Byrnes anticipates that the medical equipment provider will earn $0.00 per share for the quarter. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions’ FY2026 earnings at $0.10 EPS.

Other equities analysts have also issued reports about the stock. Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday. Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright lowered their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. KeyCorp raised their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Craig Hallum raised their target price on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Stock Performance

Shares of BioLife Solutions stock opened at $26.61 on Friday. The firm has a market capitalization of $1.23 billion, a P/E ratio of -25.10 and a beta of 1.92. BioLife Solutions has a 52 week low of $14.50 and a 52 week high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm’s 50 day moving average is $26.04 and its two-hundred day moving average is $24.35.

Insider Buying and Selling

In related news, EVP Aby J. Mathew sold 25,000 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the completion of the sale, the executive vice president now directly owns 302,046 shares of the company’s stock, valued at $6,394,313.82. This trade represents a 7.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Troy Wichterman sold 987 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 113,129 shares of company stock valued at $2,576,818 over the last three months. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds have recently modified their holdings of BLFS. Bank of New York Mellon Corp lifted its holdings in BioLife Solutions by 3.1% in the second quarter. Bank of New York Mellon Corp now owns 275,570 shares of the medical equipment provider’s stock valued at $5,905,000 after acquiring an additional 8,216 shares during the period. Rhumbline Advisers lifted its holdings in BioLife Solutions by 4.7% in the second quarter. Rhumbline Advisers now owns 87,473 shares of the medical equipment provider’s stock valued at $1,875,000 after acquiring an additional 3,912 shares during the period. Arizona State Retirement System acquired a new stake in BioLife Solutions in the second quarter valued at $217,000. Los Angeles Capital Management LLC acquired a new stake in BioLife Solutions in the second quarter valued at $430,000. Finally, Texas Permanent School Fund Corp lifted its holdings in BioLife Solutions by 8.7% in the second quarter. Texas Permanent School Fund Corp now owns 33,859 shares of the medical equipment provider’s stock valued at $726,000 after acquiring an additional 2,714 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.